Aligos Therapeutics Inc has a consensus price target of $20.5 based on the ratings of 4 analysts. The high is $70 issued by HC Wainwright & Co. on March 31, 2025. The low is $2 issued by SVB Leerink on November 3, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on March 31, 2025, March 11, 2025, and November 7, 2024, respectively. With an average price target of $71.67 between HC Wainwright & Co., there's an implied 1454.59% upside for Aligos Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/31/2025 | Buy Now | 1418.44% | HC Wainwright & Co. | Ed Arce54% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
03/11/2025 | Buy Now | 1418.44% | HC Wainwright & Co. | Ed Arce54% | $75 → $70 | Maintains | Buy | Get Alert |
11/07/2024 | Buy Now | 1526.9% | HC Wainwright & Co. | Ed Arce54% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
10/23/2024 | Buy Now | 1526.9% | HC Wainwright & Co. | Ed Arce54% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
09/20/2024 | Buy Now | 1526.9% | HC Wainwright & Co. | Ed Arce54% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
08/19/2024 | Buy Now | 1526.9% | HC Wainwright & Co. | Ed Arce54% | → $75 | Initiates | → Buy | Get Alert |
01/17/2023 | Buy Now | 51.84% | Piper Sandler | Yasmeen Rahimi50% | $75 → $175 | Maintains | Overweight | Get Alert |
01/06/2023 | Buy Now | -34.92% | Piper Sandler | Yasmeen Rahimi50% | $50 → $75 | Upgrade | Neutral → Overweight | Get Alert |
01/06/2023 | Buy Now | -34.92% | Jefferies | Michael Yee55% | $62.5 → $75 | Upgrade | Hold → Buy | Get Alert |
11/03/2022 | Buy Now | -56.62% | SVB Leerink | Roanna Ruiz33% | $75 → $50 | Maintains | Market Perform | Get Alert |
05/05/2022 | Buy Now | -34.92% | SVB Leerink | Roanna Ruiz33% | $175 → $75 | Downgrade | Outperform → Market Perform | Get Alert |
The latest price target for Aligos Therapeutics (NASDAQ:ALGS) was reported by HC Wainwright & Co. on March 31, 2025. The analyst firm set a price target for $70.00 expecting ALGS to rise to within 12 months (a possible 1418.44% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Aligos Therapeutics (NASDAQ:ALGS) was provided by HC Wainwright & Co., and Aligos Therapeutics reiterated their buy rating.
The last upgrade for Aligos Therapeutics Inc happened on January 6, 2023 when Piper Sandler raised their price target to $3. Piper Sandler previously had a neutral for Aligos Therapeutics Inc.
The last downgrade for Aligos Therapeutics Inc happened on May 5, 2022 when SVB Leerink changed their price target from $7 to $3 for Aligos Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aligos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aligos Therapeutics was filed on March 31, 2025 so you should expect the next rating to be made available sometime around March 31, 2026.
While ratings are subjective and will change, the latest Aligos Therapeutics (ALGS) rating was a reiterated with a price target of $70.00 to $70.00. The current price Aligos Therapeutics (ALGS) is trading at is $4.61, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.